Marksans Pharma share news, announcements and annual reports
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹305.20up ₹5.10 (1.70%)BSE ₹305.20
Share price at the NSE close on 28 Oct 2026. Previous close ₹300.10.
28 Oct: open ₹301.10, high ₹308.25, low ₹298.65
52-week range of traded prices to 28 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,831 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.76
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.57
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 14,05,30048.0% delivered
Marksans Pharma has 683 announcements on record, routine notices left out; 2 in the 30 days to 29 Oct 2026, the latest on 26 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Marksans Pharma quarterly results
Nov4Wed
The board meets on 4 Nov 2026 to consider financial results
Notice filed 19 Oct 2026
Marksans Pharma annual reports, presentations and earnings calls
The company's own documents, latest first.Marksans Pharma financials, year by year
Annual reports17
- Annual report, year to Mar 20264 Aug 2026
- Annual report, year to Mar 202516 Jul 2025
- Annual report, year to Mar 202431 Aug 2024
- Annual report, year to Mar 20238 Aug 2023, a zip file
- Annual report, year to Mar 20224 Aug 2022, a zip file
12 earlier reports
- Annual report, year to Mar 202130 Aug 2021, a zip file
- Annual report, year to Mar 20202 Sep 2020, a zip file
- Annual report, year to Mar 201929 Aug 2019, a zip file
- Annual report, year to Mar 20181 Oct 2018, a zip file
- Annual report, year to Mar 201711 Oct 2017, a zip file
- Annual report, year to Mar 20161 Oct 2016, a zip file
- Annual report, year to Mar 20153 Sep 2015, a zip file
- Annual report, year to Mar 201428 Aug 2014, a zip file
- Annual report, year to Mar 20125 Sep 2013, a zip file
- Annual report, year to Mar 20135 Sep 2013, a zip file
- Annual report, year to Mar 201120 Sep 2011, a zip file
- Annual report, year to Mar 20102 Sep 2010, a zip file
Investor presentations30
- Investor Presentation12 Aug 2026
- Investor Presentation26 May 2026
- Investor Presentation5 Feb 2026
- Investor Presentation13 Nov 2025
- Investor Presentation12 Aug 2025
25 earlier presentations
- Investor Presentation19 May 2025
- Investor Presentation11 Feb 2025
- Investor Presentation12 Nov 2024
- Investor Presentation13 Aug 2024
- Investor Presentation30 May 2024
- Investor Presentation13 Feb 2024
- Investor Presentation9 Nov 2023
- Investor Presentation30 May 2023
- Investor Presentation13 Feb 2023
- Investor Presentation14 Nov 2022
- Investor Presentation13 Aug 2022
- Investor Presentation30 May 2022
- Investor Presentation11 Feb 2022
- Investor Presentation10 Nov 2021
- Investor Presentation11 Aug 2021
- Investor Presentation31 May 2021
- Investor Presentation31 May 2021
- Investor Presentation8 Feb 2021
- Investor Presentation6 Nov 2020
- Investor Presentation4 Aug 2020
- Investor Presentation2 Jun 2020
- Investor Presentation11 Feb 2020
- Investor Presentation for second quarter September 30, 2019..12 Nov 2019
- Investor Presentation afresh as uploading of earlier presentation was not proper9 Aug 2019
- Investor Presentation9 Aug 2019
Earnings calls38
- Transcript of Investors/Analyst meet Q1 FY 27 Financial Results20 Aug 2026
- Link of Recording of Conference call Q1 FY 27 Financial Results13 Aug 2026
- Transcript of Investors/Analyst meet on Q4 FY 26 Audited Financial Results3 Jun 2026
- Audio Recording of investor(s) / analyst(s) meet Conference Call on Q4 FY26 Financial Results27 May 2026
- Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 202612 Feb 2026
33 earlier call documents
- Link of Recording6 Feb 2026
- Audio Recording of investor(s) / analyst(s) meet Conference Call on Q3 & 9M FY26 Financial Results6 Feb 2026
- Transcript21 Nov 2025
- Link of Recording14 Nov 2025
- Transcript19 Aug 2025
- Link of Recording13 Aug 2025
- Transcript26 May 2025
- Link of Recording20 May 2025
- Transcript25 Feb 2025
- Link of Recording12 Feb 2025
- Transcript25 Nov 2024
- Link of Recording13 Nov 2024
- Transcript22 Aug 2024
- Link of Recording14 Aug 2024
- Transcript of investor(s)/analyst(s) meet of Q4FY2024 financial performance and strategy update5 Jun 2024
- Link of Recording31 May 2024
- Transcript20 Feb 2024
- Link of Recording14 Feb 2024
- Transcript16 Nov 2023
- Link of Recording9 Nov 2023
- Transcript22 Aug 2023
- Link of Recording of Q1 Financial Results Conference call17 Aug 2023
- Transcript7 Jun 2023
- Link of Recording31 May 2023
- Transcript21 Feb 2023
- Link of Recording http://marksanspharma.com/investors-meet.html14 Feb 2023
- Transcript of Analysts/Institutional Investor Meet/Con. Call21 Nov 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call16 Nov 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call19 Aug 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call17 Aug 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call6 Jun 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call1 Jun 2022
- This is further to our letter dated 8th February, 2021, regarding intimation of schedule of conference call held on 10th February, 2021. We enclosed herewith the transcript of the said conference call.19 Feb 2021
Marksans Pharma share news and announcements
Newest first. Page 1 of 14.
Oct 2026
26 Oct · Analysts
Sep 2026
17 Sep · General Updates
1 Sep · Analysts
Aug 2026
12 Aug · Results
4 Aug · Updates
3 Aug · Analysts
Jul 2026
20 Jul · General Updates
17 Jul · General Updates
3 Jul · Board meeting
Jun 2026
26 Jun · Updates
23 Jun · General Updates
16 Jun · General Updates
8 Jun · Analysts
2 Jun · General Updates
May 2026
26 May · Results
25 May · Disclosure
Apr 2026
Mar 2026
11 Mar · General Updates
10 Mar · General Updates
Feb 2026
Jan 2026
27 Jan · General Updates
Nov 2025
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 12 Aug 2026Resultsup 12.06%+12.1 pts vs Nifty 500market median −0.7% · five sessions +17.0% (+17.9 pts vs Nifty 500) · volume 35.8× usual · delivery −35.2 pts against usual · The announcement
- 9 Jun 2026Credit ratingup 7.07%+6.2 pts vs Nifty 500market median 0.0% · five sessions +5.8% (+2.6 pts vs Nifty 500) · volume 1.3× usual · delivery −0.8 pts against usual · The announcement
- 26 May 2026Resultsup 15.68%+15.8 pts vs Nifty 500market median −0.7% · five sessions +9.5% (+11.3 pts vs Nifty 500) · volume 16.8× usual · delivery −27.0 pts against usual · The announcement
- 5 Feb 2026Resultsup 1.35%+1.9 pts vs Nifty 500market median −0.7% · five sessions +5.9% (+4.8 pts vs Nifty 500) · volume 2.5× usual · delivery −31.2 pts against usual · The announcement
- 14 Nov 2025Resultsup 2.17%+2.1 pts vs Nifty 500market median −0.7% · five sessions +2.5% (+1.8 pts vs Nifty 500) · volume 1.7× usual · delivery −4.1 pts against usual · The announcement
- 8 Oct 2025Credit ratingdown 0.48%−0.1 pts vs Nifty 500market median 0.0% · five sessions +9.7% (+9.8 pts vs Nifty 500) · volume 0.6× usual · delivery −2.6 pts against usual · The announcement
- 12 Aug 2025Resultsdown 11.11%−10.8 pts vs Nifty 500market median −0.7% · five sessions −12.3% (−14.2 pts vs Nifty 500) · volume 8.6× usual · delivery −20.2 pts against usual · The announcement
- 20 May 2025Dividenddown 6.60%−5.4 pts vs Nifty 500market median 0.0% · five sessions −0.7% (−0.8 pts vs Nifty 500) · volume 1.5× usual · delivery +2.4 pts against usual · The announcement
- 1 Apr 2025Board or managers changeddown 0.22%+1.0 pts vs Nifty 500market median 0.0% · five sessions −12.5% (−6.7 pts vs Nifty 500) · volume 0.5× usual · delivery −3.8 pts against usual · The announcement
- 5 Mar 2025Credit ratingdown 0.56%−2.3 pts vs Nifty 500market median 0.0% · five sessions +0.6% (−1.3 pts vs Nifty 500) · volume 1.3× usual · delivery +19.0 pts against usual · The announcement
20 earlier announcements
- 12 Nov 2024Resultsup 4.12%+5.3 pts vs Nifty 500market median −0.7% · five sessions +5.8% (+8.4 pts vs Nifty 500) · volume 4.9× usual · delivery −17.2 pts against usual · The announcement
- 29 Oct 2024Credit ratingdown 0.53%−1.2 pts vs Nifty 500market median 0.0% · five sessions +4.6% (+5.1 pts vs Nifty 500) · volume 0.4× usual · delivery −6.0 pts against usual · The announcement
- 10 Jul 2024Board or managers changedup 0.59%+1.0 pts vs Nifty 500market median 0.0% · five sessions +0.3% (−0.3 pts vs Nifty 500) · volume 2.5× usual · delivery −9.8 pts against usual · The announcement
- 30 May 2024Dividenddown 13.57%−12.5 pts vs Nifty 500market median 0.0% · five sessions −12.8% (−11.8 pts vs Nifty 500) · volume 9.3× usual · delivery −3.5 pts against usual · The announcement
- 8 Dec 2023Credit ratingup 1.19%+1.2 pts vs Nifty 500market median 0.0% · five sessions +2.9% (+1.4 pts vs Nifty 500) · volume 0.1× usual · delivery +13.4 pts against usual · The announcement
- 12 Oct 2023Credit ratingup 1.71%+1.6 pts vs Nifty 500market median 0.0% · five sessions +2.5% (+2.9 pts vs Nifty 500) · volume 2.5× usual · delivery −9.1 pts against usual · The announcement
- 31 May 2023Board or managers changedup 5.24%+5.5 pts vs Nifty 500market median 0.0% · five sessions +10.5% (+10.0 pts vs Nifty 500) · volume 6.5× usual · delivery −16.5 pts against usual · The announcement
- 30 May 2023Dividendup 7.00%+6.8 pts vs Nifty 500market median 0.0% · five sessions +16.9% (+16.3 pts vs Nifty 500) · volume 14.6× usual · delivery −25.5 pts against usual · The announcement
- 25 May 2023Dividendup 1.39%+1.1 pts vs Nifty 500market median 0.0% · five sessions +18.1% (+16.5 pts vs Nifty 500) · volume 0.5× usual · delivery −4.0 pts against usual · The announcement
- 7 Feb 2023Credit ratingup 2.48%+2.7 pts vs Nifty 500market median 0.0% · five sessions +5.9% (+6.2 pts vs Nifty 500) · volume 0.4× usual · delivery +3.5 pts against usual · The announcement
- 17 Jan 2023Buybackup 0.30%−0.3 pts vs Nifty 500market median 0.0% · five sessions −1.7% (−2.4 pts vs Nifty 500) · volume 0.6× usual · delivery −3.6 pts against usual · The announcement
- 16 Jan 2023Buybackup 0.08%+0.3 pts vs Nifty 500market median 0.0% · five sessions +1.9% (+1.9 pts vs Nifty 500) · volume 0.8× usual · delivery −14.5 pts against usual · The announcement
- 26 Jul 2022Buybackdown 0.10%+0.9 pts vs Nifty 500market median 0.0% · five sessions −0.8% (−4.8 pts vs Nifty 500) · volume 0.2× usual · delivery +25.3 pts against usual · The announcement
- 25 Jul 2022Buybackdown 0.50%−0.1 pts vs Nifty 500market median 0.0% · five sessions −1.6% (−3.9 pts vs Nifty 500) · volume 0.1× usual · delivery +17.7 pts against usual · The announcement
- 22 Jul 2022Buybackdown 1.59%−2.0 pts vs Nifty 500market median 0.0% · five sessions −3.2% (−4.6 pts vs Nifty 500) · volume 0.3× usual · delivery +8.4 pts against usual · The announcement
- 21 Jul 2022Buybackup 2.34%+1.6 pts vs Nifty 500market median 0.0% · five sessions −0.5% (−1.2 pts vs Nifty 500) · volume 1.1× usual · delivery −13.4 pts against usual · The announcement
- 20 Jul 2022Buybackdown 0.20%−1.0 pts vs Nifty 500market median 0.0% · five sessions −0.1% (−0.7 pts vs Nifty 500) · volume 0.2× usual · delivery +22.7 pts against usual · The announcement
- 19 Jul 2022Buybackup 0.20%−0.3 pts vs Nifty 500market median 0.0% · five sessions +0.2% (−1.9 pts vs Nifty 500) · volume 0.2× usual · delivery +15.8 pts against usual · The announcement
- 18 Jul 2022Buyback0.00%−1.4 pts vs Nifty 500market median 0.0% · five sessions +0.7% (−3.3 pts vs Nifty 500) · volume 0.3× usual · delivery +13.5 pts against usual · The announcement
- 12 Jul 2022Buybackdown 1.62%−0.8 pts vs Nifty 500market median 0.0% · five sessions −0.6% (−1.3 pts vs Nifty 500) · volume 0.4× usual · delivery −1.3 pts against usual · The announcement
Marksans Pharma results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.